Log in

NASDAQ:RDHLREDHILL BIOPHAR/S Stock Price, Forecast & News

$7.99
+0.49 (+6.53 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.52
Now: $7.99
$8.03
50-Day Range
$6.34
MA: $6.96
$7.93
52-Week Range
$3.26
Now: $7.99
$9.12
Volume317,296 shs
Average Volume334,154 shs
Market Capitalization$281.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors. It is also developing YELIVA that is in Phase IIa clinical trial for the treatment of advanced unresectable cholangiocarcinoma; is in Phase Ib/II clinical trial for refractory or relapsed multiple myeloma; and is in Phase II clinical trial for the treatment of advanced hepatocellular carcinoma. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Read More
REDHILL BIOPHAR/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDHL
CUSIPN/A
Phone972-3541-3131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.29 million
Book Value$2.74 per share

Profitability

Net Income$-42,300,000.00
Net Margins-883.97%

Miscellaneous

Employees75
Market Cap$281.81 million
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable
$7.99
+0.49 (+6.53 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions

How has REDHILL BIOPHAR/S's stock been impacted by COVID-19 (Coronavirus)?

REDHILL BIOPHAR/S's stock was trading at $3.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RDHL stock has increased by 100.3% and is now trading at $7.99.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of REDHILL BIOPHAR/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for REDHILL BIOPHAR/S
.

When is REDHILL BIOPHAR/S's next earnings date?

REDHILL BIOPHAR/S is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for REDHILL BIOPHAR/S
.

How were REDHILL BIOPHAR/S's earnings last quarter?

REDHILL BIOPHAR/S (NASDAQ:RDHL) announced its earnings results on Wednesday, May, 27th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.12. The biotechnology company had revenue of $1.06 million for the quarter, compared to analyst estimates of $3.79 million. REDHILL BIOPHAR/S had a negative net margin of 883.97% and a negative return on equity of 125.23%.
View REDHILL BIOPHAR/S's earnings history
.

What price target have analysts set for RDHL?

1 brokers have issued 12-month target prices for REDHILL BIOPHAR/S's stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate REDHILL BIOPHAR/S's stock price to reach $14.50 in the next year. This suggests a possible upside of 81.5% from the stock's current price.
View analysts' price targets for REDHILL BIOPHAR/S
.

Has REDHILL BIOPHAR/S been receiving favorable news coverage?

Media headlines about RDHL stock have been trending positive this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. REDHILL BIOPHAR/S earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about REDHILL BIOPHAR/S
.

Who are some of REDHILL BIOPHAR/S's key competitors?

What other stocks do shareholders of REDHILL BIOPHAR/S own?

Who are REDHILL BIOPHAR/S's key executives?

REDHILL BIOPHAR/S's management team includes the following people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 53)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 50)
  • Mr. Gilead Raday, Chief Operating Officer (Age 44)
  • Mr. Adi Frish, Sr. VP of Bus. Devel. & Licensing (Age 49)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 43)

What is REDHILL BIOPHAR/S's stock symbol?

REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL."

Who are REDHILL BIOPHAR/S's major shareholders?

REDHILL BIOPHAR/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Creative Planning (2.22%), Candriam Luxembourg S.C.A. (0.23%), CLARET ASSET MANAGEMENT Corp (0.13%) and Ingalls & Snyder LLC (0.06%).

Which major investors are selling REDHILL BIOPHAR/S stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including CLARET ASSET MANAGEMENT Corp.

Which major investors are buying REDHILL BIOPHAR/S stock?

RDHL stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, Candriam Luxembourg S.C.A., and Ingalls & Snyder LLC.

How do I buy shares of REDHILL BIOPHAR/S?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is REDHILL BIOPHAR/S's stock price today?

One share of RDHL stock can currently be purchased for approximately $7.99.

How big of a company is REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S has a market capitalization of $281.81 million and generates $6.29 million in revenue each year. The biotechnology company earns $-42,300,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. REDHILL BIOPHAR/S employs 75 workers across the globe.

What is REDHILL BIOPHAR/S's official website?

The official website for REDHILL BIOPHAR/S is www.redhillbio.com.

How can I contact REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.